Evidence map›Paper›PMID 27579533›Full record

ArticleOncotarget2016

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21.

Mingfeng Zhang, Zhaoming Wang, Ofure Obazee, Jinping Jia, Erica J Childs, Jason Hoskins, Gisella Figlioli, Evelina Mocci, Irene Collins, Charles C Chung and 113 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Allelic effects onmedRxiv : the preprint server for health sciences · 2024
    Article
  15. Article
  16. Article
  17. Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  18. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

123 authors at 20 institutions in 17 countries.

Mingfeng ZhangLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Zhaoming WangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ofure ObazeeGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jinping JiaLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Erica J ChildsDepartment of Oncology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jason HoskinsLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gisella FiglioliGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Evelina MocciDepartment of Oncology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Irene CollinsLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Charles C ChungDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Christopher HautmanLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Alan A ArslanDepartment of Obstetrics and Gynecology, New York University School of Medicine, New York, New York, USA.
Laura Beane-FreemanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Julie BuringDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Eric J DuellUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), Barcelona, Spain.
Steven GallingerLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
Gary E GoodmanDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Phyllis J GoodmanSouthwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Aruna KamineniGroup Health Research Institute, Seattle, Washington, USA,.
Laurence N KolonelCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Matthew H KulkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Núria MalatsGenetic and Molecular Epidemiology Group, CNIO-Spanish National Cancer Research Centre, Madrid, Spain.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Howard D SessoDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
Kala VisvanathanJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Emily WhiteDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Wei ZhengDivision of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Christian C AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gabriella AndreottiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lauren BraisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
H Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Daniela BassoDepartment of Laboratory Medicine, University Hospital of Padova, Padua, Italy,.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Marie-Christine Boutron-RuaultInserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health Team, F-94805, Villejuif, France.
Maarten F BijlsmaLaboratory for Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Laurie BurdetteDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gabriele CapursoDigestive and Liver Disease Unit, 'Sapienza' University of Rome, Rome, Italy.
Giulia Martina CavestroGastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Michelle CotterchioPrevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario, Canada.
Eithne CostelloNational Institute for Health Research Liverpool Pancreas Biomedical Research Unit, University of Liverpool, Liverpool, United Kingdom.
Joanne ElenaDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ugo BoggiDepartment of Surgery, Unit of Experimental Surgical Pathology, University Hospital of Pisa, Pisa, Italy.
J Michael GazianoDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Maria GazouliDepartment of Basic Medical Sciences, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Edward L GiovannucciDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
Michael GogginsDepartment of Pathology, Sidney Kimmel Cancer Center and Johns Hopkins University, Baltimore, Maryland, USA.
Myron GrossLaboratory of Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Christopher A HaimanPreventive Medicine, University of Southern California, Los Angeles, California, USA.
Manal HassanDepartment of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Kathy J HelzlsouerDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Nan HuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
David J HunterDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Elzbieta Iskierka-JazdzewskaDepartment of Hematology, Medical University of Łodz, Łodz, Poland.
Mazda JenabInternational Agency for Research on Cancer (IARC), Lyon, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Timothy J KeyCancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
Kay-Tee KhawSchool of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Manolis KogevinasCentre de Recerca en Epidemiologia Ambiental (CREAL), CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Juozas KupcinskasDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Robert C KurtzDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Maria T LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stefano LandiDepartment of Biology, University of Pisa, Pisa, Italy.
Loic Le MarchandCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Andrea MambriniOncology Department, ASL1 Massa Carrara, Massa Carrara, Italy.
Satu MannistoNational Institute for Health and Welfare, Department of Chronic Disease Prevention, Helsinki, Finland.
Roger L MilneCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
Rachel E NealeDepartment of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Ann L ObergDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Salvatore PanicoDipartimento di Medicina Clinica E Chirurgia, Federico II Univeristy, Naples, Italy.
Alpa V PatelEpidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
Petra H M PeetersJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Ulrike PetersDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Raffaele PezzilliPancreas Unit, Department of Digestive Diseases and Internal Medicine, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Miquel PortaHospital del Mar Institute of Medical Research (IMIM), Barcelona, Spain.
Mark PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
J Ramón QuirosPublic Health and Participation Directorate, Asturias, Spain.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Aldo ScarpaARC-NET: Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, Italy.
Ghislaine SceloInternational Agency for Research on Cancer (IARC), Lyon, France.
Xiao-Ou ShuDivision of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Debra T SilvermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Pavel SoucekLaboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
Oliver StrobelDepartment of General Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Malin SundDepartment of Surgical and Peroperative Sciences, Umeå University, Umeå, Sweden.
Ewa Małecka-PanasDepartment of Digestive Tract Diseases, Medical University of Łodz, Łodz, Poland.
Philip R TaylorDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Francesca TavanoDivision of Gastroenterology and Research Laboratory, IRCCS Scientific Institute and Regional General Hospital "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy.
Ruth C TravisCancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
Mark ThornquistDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Anne TjønnelandInstitute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.
Geoffrey S TobiasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Dimitrios TrichopoulosDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
Yogesh VashistDepartment of General, Visceral and Thoracic Surgery, University Hamburg-Eppendorf, Hamburg, Germany.
Pavel VodickaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Jean Wactawski-WendeDepartment of Social and Preventive Medicine, University at Buffalo, Buffalo, New York, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Herbert YuCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Kai YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anne Zeleniuch-JacquotteDepartment of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA,.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Eric J JacobsEpidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
Donghui LiDepartment of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Charles FuchsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Robert HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Patricia HartgeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gloria M PetersenDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Rachael S Stolzenberg-SolomonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Brian M WolpinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Peter KraftDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
Alison P KleinDepartment of Oncology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Laufey T AmundadottirLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USNational Cancer Institute · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEHarvard University · USJohns Hopkins University · USDana-Farber Cancer Institute · USAmerican Cancer Society · USBrigham and Women's Hospital · USCancer Research UK Oxford Centre · GBCentre International de Recherche sur le Cancer · FRImperial College London · GBMayo Clinic in Florida · USMedical University of Lodz · PLMemorial Sloan Kettering Cancer Center · USNew York University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Pisa · ITVanderbilt University Medical Center · USAcademic Medical Center · NL

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
The Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4M
Circulating Biomarker Consortium for Pancreatic Cancer Early DetectionU01CA210171 · NCI · DANA-FARBER CANCER INST · PI Michael H. Rosenthal, Brian Matthew Wolpin · 2016 to 2026
$8.7M
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)R01CA154823 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2011 to 2020
$5.7M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
Cancer Research UK 14136Cancer Research UK 16491Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/N003284/1NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA154823NCI NIH HHS U01 CA210171NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA182913World Health Organization 001
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have identified common pancreatic cancer susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify new susceptibility variants, we performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS. This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8). These SNPs represent independent risk variants at previously identified pancreatic cancer risk loci on chr1q32.1 ( NR5A2), chr8q24.21 ( MYC) and chr5p15.33 ( CLPTM1L- TERT) as per analyses conditioned on previously reported susceptibility variants. We assessed expression of candidate genes at the three risk loci in histologically normal ( n = 10) and tumor ( n = 8) derived pancreatic tissue samples and observed a marked reduction of NR5A2 expression (chr1q32.1) in the tumors (fold change -7.6, P = 5.7x10 -8). This finding was validated in a second set of paired ( n = 20) histologically normal and tumor derived pancreatic tissue samples (average fold change for three NR5A2 isoforms -31.3 to -95.7, P = 7.5x10 -4-2.0x10 -3). Our study has identified new susceptibility variants independently conferring pancreatic cancer risk that merit functional follow-up to identify target genes and explain the underlying biology.

Indexed as

Chromosomes, Human, Pair 1Chromosomes, Human, Pair 5Chromosomes, Human, Pair 8Datasets as TopicGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansPancreatic NeoplasmsPolymorphism, Single Nucleotidefine-mappingGWASimputationNR5A2pancreatic cancer

Identifiers

PMID27579533
PMCPMC5340084
OpenAlexW2509403461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.